Janux Therapeutics, Inc. Common Stock (JANX)

Price$15.87

Favorite Metrics

Price vs S&P 500 (26W)-49.07%

Price vs S&P 500 (4W)3.02%

Market Capitalization$962.36M

All Metrics

Book Value / Share (Quarterly)$15.85

P/TBV (Annual)1.33x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)5.12%

Cash Flow / Share (Quarterly)$-1.38

Price vs S&P 500 (YTD)10.50%

Net Profit Margin (TTM)-243.13%

EPS (TTM)$-1.83

10-Day Avg Trading Volume0.85M

EPS Excl Extra (TTM)$-1.83

EPS (Annual)$-1.83

ROI (Annual)-6.74%

Net Profit Margin (5Y Avg)-827.80%

Cash / Share (Quarterly)$16.01

Revenue Growth QoQ (YoY)2177.90%

ROA (Last FY)-6.50%

Revenue Growth TTM (YoY)-5.55%

EBITD / Share (TTM)$-2.51

ROE (5Y Avg)-29.83%

Operating Margin (TTM)-352.51%

Cash Flow / Share (Annual)$-0.75

P/B Ratio1.01x

P/B Ratio (Quarterly)0.87x

Net Income / Employee (Annual)$-1

EV / Revenue (TTM)91.00x

Net Interest Coverage (TTM)-2.49x

ROA (TTM)-11.06%

EPS Incl Extra (Annual)$-1.83

Current Ratio (Annual)60.82x

Quick Ratio (Quarterly)38.92x

3-Month Avg Trading Volume1.49M

52-Week Price Return-44.86%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$7.56

P/S Ratio (Annual)96.24x

Asset Turnover (Annual)0.01x

52-Week High$35.34

Operating Margin (5Y Avg)-1019.40%

EPS Excl Extra (Annual)$-1.83

26-Week Price Return-40.32%

Quick Ratio (Annual)60.32x

13-Week Price Return12.04%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)39.04x

Enterprise Value$910.023

Asset Turnover (TTM)0.01x

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-1136.25%

Cash / Share (Annual)$17.37

3-Month Return Std Dev50.45%

Net Income / Employee (TTM)$-1

ROE (Last FY)-6.74%

EPS Basic Excl Extra (Annual)$-1.83

Receivables Turnover (TTM)11.06x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.83

ROI (TTM)-11.55%

P/S Ratio (TTM)96.24x

Pretax Margin (5Y Avg)-827.80%

Revenue / Share (Annual)$0.16

Tangible BV / Share (Annual)$7.71

Price vs S&P 500 (52W)-79.95%

Year-to-Date Return14.64%

5-Day Price Return6.17%

EPS Normalized (Annual)$-1.83

ROA (5Y Avg)-17.92%

Net Profit Margin (Annual)-1136.25%

Month-to-Date Return13.81%

Cash Flow / Share (TTM)$-1.42

EBITD / Share (Annual)$-2.51

Operating Margin (Annual)-1576.67%

ROI (5Y Avg)-29.83%

EPS Basic Excl Extra (TTM)$-1.83

P/TBV (Quarterly)1.22x

P/B Ratio (Annual)3.02x

Pretax Margin (TTM)-243.13%

Book Value / Share (Annual)$17.34

Price vs S&P 500 (13W)9.17%

Beta2.73x

Revenue / Share (TTM)$0.16

ROE (TTM)-11.55%

52-Week Low$12.12

Analyst Recommendations

Jan 2026

Feb 2026

Mar 2026

Apr 2026

4.27

4.23

Industry Peers — Pharmaceuticals(308)

Symbol	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
JANXJanux Therapeutics, Inc. Common Stock	96.24x	-5.55%	—	—	$15.87
LLYEli Lilly & Co.	13.45x	44.70%	83.04%	27.59%	$919.90
JNJJohnson & Johnson	5.82x	7.87%	67.95%	14.90%	$230.69
ABBVABBVIE INC.	5.97x	8.57%	71.62%	-2.88%	$203.71
MRKMerck & Co., Inc.	4.51x	1.31%	78.55%	21.23%	$117.10
AZNAstraZeneca PLC	5.39x	8.63%	81.31%	21.88%	$200.69
NVSNovartis AG	4.87x	8.91%	75.82%	15.26%	$150.99
NVONovo-Nordisk A/S	3.74x	6.43%	80.98%	20.66%	$40.46
ABTAbbott Laboratories	3.71x	6.59%	56.50%	8.20%	$96.00
PFEPfizer Inc.	2.50x	-1.64%	75.81%	-3.51%	$27.52
BMYBristol-Myers Squibb Co.	2.52x	-0.22%	72.63%	—	$59.13

About

Janux Therapeutics is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies designed to treat cancer by engaging the patient's immune system. The company has developed proprietary platforms, including TRACTr (tumor-activated T cell engagers) and TRACIr (tumor-activated immunomodulators), that combine tumor-targeting with immune activation mechanisms. These approaches aim to activate anti-cancer immune responses specifically at tumor sites, potentially improving efficacy and safety compared to conventional cancer treatments.